Poland
· Delayed Price · Currency is PLN Pure Biologics Statistics
Total Valuation
Pure Biologics has a market cap or net worth of PLN 74.59 million. The enterprise value is 82.56 million.
| Market Cap | 74.59M |
| Enterprise Value | 82.56M |
Important Dates
The last earnings date was Thursday, September 19, 2024.
| Earnings Date | Sep 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pure Biologics has 3.69 million shares outstanding. The number of shares has increased by 32.26% in one year.
| Shares Outstanding | 3.69M |
| Shares Change (YoY) | +32.26% |
| Shares Change (QoQ) | +2.30% |
| Owned by Insiders (%) | 14.02% |
| Owned by Institutions (%) | 8.29% |
| Float | 2.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.46 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.14 |
Financial Position
The company has a current ratio of 1.95
| Current Ratio | 1.95 |
| Quick Ratio | 1.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.83 |
| Interest Coverage | -8.63 |
Financial Efficiency
Return on equity (ROE) is -250.95% and return on invested capital (ROIC) is -50.23%.
| Return on Equity (ROE) | -250.95% |
| Return on Assets (ROA) | -38.56% |
| Return on Capital (ROIC) | -50.23% |
| Revenue Per Employee | 2,379 |
| Profits Per Employee | -1.16M |
| Employee Count | 51 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.06% in the last 52 weeks. The beta is 1.49, so Pure Biologics's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | +43.06% |
| 50-Day Moving Average | 22.76 |
| 200-Day Moving Average | 12.69 |
| Relative Strength Index (RSI) | 45.48 |
| Average Volume (20 Days) | 193,778 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pure Biologics had revenue of PLN 69,000 and -33.62 million in losses. Loss per share was -10.34.
| Revenue | 69,000 |
| Gross Profit | -1.68M |
| Operating Income | -28.44M |
| Pretax Income | -33.63M |
| Net Income | -33.62M |
| EBITDA | -22.94M |
| EBIT | -28.44M |
| Loss Per Share | -10.34 |
Balance Sheet
The company has 5.29 million in cash and 13.26 million in debt, giving a net cash position of -7.97 million or -2.16 per share.
| Cash & Cash Equivalents | 5.29M |
| Total Debt | 13.26M |
| Net Cash | -7.97M |
| Net Cash Per Share | -2.16 |
| Equity (Book Value) | -3.08M |
| Book Value Per Share | -0.92 |
| Working Capital | 9.11M |
Cash Flow
In the last 12 months, operating cash flow was -15.94 million and capital expenditures -119,000, giving a free cash flow of -16.06 million.
| Operating Cash Flow | -15.94M |
| Capital Expenditures | -119,000 |
| Free Cash Flow | -16.06M |
| FCF Per Share | -4.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | -41,221.74% |
| Pretax Margin | -48,734.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -23,276.81% |
Dividends & Yields
Pure Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.26% |
| Shareholder Yield | -32.26% |
| Earnings Yield | -51.17% |
| FCF Yield | -21.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pure Biologics has an Altman Z-Score of -9.99. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.99 |
| Piotroski F-Score | n/a |